Synthetic ghrelin - Oxeia Biopharmaceuticals

Drug Profile

Synthetic ghrelin - Oxeia Biopharmaceuticals

Alternative Names: OXE-103; SUN 11031 - KineMed

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biopharma Forest; University of California, San Diego
  • Developer KineMed; Oxeia Biopharmaceuticals
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries
  • Discontinued Muscular atrophy

Most Recent Events

  • 02 Aug 2017 Oxeia Biopharmaceuticals plans phase II studies for Brain injuries in early 2018
  • 02 Aug 2017 Synthetic ghrelin licensed to Oxeia Biopharmaceuticals
  • 02 Aug 2017 Discontinued - Phase-II for Muscular atrophy in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top